Paradigm Biocapital Advisors LP is an SEC-registered investment adviser based in New York, NY that reports managing 2 hedge funds on Form ADV. It reports $4.5 billion in regulatory assets under management. Its private funds, of all types, hold $4.1 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +31.4% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +81.1% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $4.5 billionForm ADV Item 5.F
- Gross assets of private funds
- $4.1 billionAll private fund types, Form ADV
- Hedge funds managed
- 22 private funds in total
- Employees
- 11Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 312544
- Latest Form ADV
- 08/27/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +15.8% | +14.8% |
| Q1 2026 | +13.5% | -4.6% |
| Q4 2025 | +24.5% | +2.4% |
| Q3 2025 | +31.2% | +7.8% |
| Q2 2025 | -0.3% | +10.4% |
| Q1 2025 | -19.3% | -4.5% |
| Q4 2024 | -10.3% | +2.1% |
| Q3 2024 | +16.8% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 30 share positions ($5,028,958,519) reported by Paradigm Biocapital Advisors LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Revolution Medicines Inc25.38%
- Genmab A/s10.03%
- Edgewise Therapeutics Inc8.70%
- Spyre Therapeutics Inc7.89%
- Insmed Inc6.12%
- MBX Biosciences Inc4.40%
- Oruka Therapeutics Inc4.13%
- Belite Bio Inc3.86%
- Tarsus Pharmaceuticals Inc3.60%
- Tango Therapeutics Inc3.45%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Revolution Medicines Inc | $1,276,578,239 | 25.38% | 6,219,323 | -2.23% |
| Genmab A/s | $504,318,639 | 10.03% | 14,136,472 | +7.64% |
| Edgewise Therapeutics Inc | $437,613,799 | 8.70% | 10,778,665 | +5.51% |
| Spyre Therapeutics Inc | $396,846,774 | 7.89% | 4,457,450 | +16.06% |
| Insmed Inc | $307,718,815 | 6.12% | 2,695,977 | +103.32% |
| MBX Biosciences Inc | $221,166,519 | 4.40% | 3,772,885 | +50.43% |
| Oruka Therapeutics Inc | $207,684,198 | 4.13% | 2,493,507 | +16.27% |
| Belite Bio Inc | $193,955,328 | 3.86% | 1,142,123 | -7.36% |
| Tarsus Pharmaceuticals Inc | $180,911,089 | 3.60% | 2,301,375 | -17.09% |
| Tango Therapeutics Inc | $173,690,573 | 3.45% | 6,961,546 | +9.50% |
| Viridian Therapeutics Inc | $170,025,466 | 3.38% | 8,257,672 | +22.81% |
| Bridgebio Pharma Inc | $154,488,530 | 3.07% | 2,347,850 | New |
| Vaxcyte Inc | $121,928,279 | 2.42% | 2,142,852 | +0.70% |
| Erasca Inc | $117,254,448 | 2.33% | 7,998,257 | -16.25% |
| Jade Biosciences Inc | $85,048,415 | 1.69% | 6,053,268 | +111.84% |
| Tyra Biosciences Inc | $76,771,573 | 1.53% | 3,510,360 | +91.97% |
| Olema Pharmaceuticals Inc | $75,345,777 | 1.50% | 8,720,576 | +0.58% |
| Obsidian Therapeutics Inc | $57,051,088 | 1.13% | 4,155,214 | New |
| Structure Therapeutics Inc | $40,625,953 | 0.81% | 1,299,199 | New |
| Achieve Life Science Inc | $40,060,515 | 0.80% | 4,951,856 | Unchanged |
| Veradermics Inc | $37,588,574 | 0.75% | 310,060 | New |
| Assembly Biosciences Inc | $36,497,541 | 0.73% | 1,553,748 | Unchanged |
| Oric Pharmaceuticals Inc | $20,282,708 | 0.40% | 1,505,769 | New |
| Korsana Biosciences Inc | $19,645,248 | 0.39% | 613,914 | New |
| Editas Medicine Inc | $19,468,110 | 0.39% | 7,575,140 | +35.59% |
| Hemab Therapeutics Hldgs Inc | $19,409,061 | 0.39% | 629,347 | New |
| Vor Biopharma Inc | $16,973,091 | 0.34% | 889,575 | -49.17% |
| Kardigan Inc | $13,275,000 | 0.26% | 900,000 | Unchanged |
| Tcgx Acquisition Corp | $3,753,000 | 0.07% | 300,000 | New |
| Inventiva SA | $2,982,169 | 0.06% | 808,176 | -79.80% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 8 new positions, 6 sold out, 13 increased, 6 reduced and 3 unchanged.
Number of positions (a count, not dollars)
- New positions8
- Increased13
- Unchanged3
- Reduced6
- Sold out6
New positions
| Stock | Value | Shares |
|---|---|---|
| Bridgebio Pharma Inc | $154,488,530 | 2,347,850 |
| Obsidian Therapeutics Inc | $57,051,088 | 4,155,214 |
| Structure Therapeutics Inc | $40,625,953 | 1,299,199 |
| Veradermics Inc | $37,588,574 | 310,060 |
| Oric Pharmaceuticals Inc | $20,282,708 | 1,505,769 |
| Korsana Biosciences Inc | $19,645,248 | 613,914 |
| Hemab Therapeutics Hldgs Inc | $19,409,061 | 629,347 |
| Tcgx Acquisition Corp | $3,753,000 | 300,000 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Nuvalent Inc | $731,667,476 | 5,924,433 |
| Apogee Therapeutics Inc | $209,233,581 | 1,576,385 |
| Alnylam Pharmaceuticals Inc | $144,494,400 | 480,000 |
| Eyepoint Inc | $41,332,677 | 2,890,397 |
| Maplight Therapeutics Inc | $24,580,936 | 685,852 |
| Lexeo Therapeutics Inc | $19,436,403 | 4,175,382 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Insmed Inc | +1,370,000 | +103.32% | $307,718,815 | 2,695,977 |
| MBX Biosciences Inc | +1,264,870 | +50.43% | $221,166,519 | 3,772,885 |
| Spyre Therapeutics Inc | +616,672 | +16.06% | $396,846,774 | 4,457,450 |
| Jade Biosciences Inc | +3,195,863 | +111.84% | $85,048,415 | 6,053,268 |
| Tyra Biosciences Inc | +1,681,753 | +91.97% | $76,771,573 | 3,510,360 |
| Genmab A/s | +1,003,341 | +7.64% | $504,318,639 | 14,136,472 |
| Viridian Therapeutics Inc | +1,533,884 | +22.81% | $170,025,466 | 8,257,672 |
| Oruka Therapeutics Inc | +348,981 | +16.27% | $207,684,198 | 2,493,507 |
| Edgewise Therapeutics Inc | +563,210 | +5.51% | $437,613,799 | 10,778,665 |
| Tango Therapeutics Inc | +604,023 | +9.50% | $173,690,573 | 6,961,546 |
| Editas Medicine Inc | +1,988,515 | +35.59% | $19,468,110 | 7,575,140 |
| Vaxcyte Inc | +15,000 | +0.70% | $121,928,279 | 2,142,852 |
| Olema Pharmaceuticals Inc | +50,000 | +0.58% | $75,345,777 | 8,720,576 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Tarsus Pharmaceuticals Inc | -474,274 | -17.09% | $180,911,089 | 2,301,375 |
| Revolution Medicines Inc | -142,000 | -2.23% | $1,276,578,239 | 6,219,323 |
| Erasca Inc | -1,551,743 | -16.25% | $117,254,448 | 7,998,257 |
| Vor Biopharma Inc | -860,425 | -49.17% | $16,973,091 | 889,575 |
| Belite Bio Inc | -90,754 | -7.36% | $193,955,328 | 1,142,123 |
| Inventiva SA | -3,191,824 | -79.80% | $2,982,169 | 808,176 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Jade Biosciences, Inc. | 13G amendment | 9.5% | 6,053,268 | Nov 16, 2026 | SEC.gov ↗ |
| Viridian Therapeutics, Inc. | 13G amendment | 7.3% | 8,257,672 | Nov 16, 2026 | SEC.gov ↗ |
| Lexeo Therapeutics, Inc. | 13G amendment | 0% | 0 | Nov 16, 2026 | SEC.gov ↗ |
| Nuvalent, Inc. | 13G amendment | 0% | 0 | Nov 16, 2026 | SEC.gov ↗ |
| Tarsus Pharmaceuticals, Inc. | 13G amendment | 4.7% | 2,301,375 | Nov 16, 2026 | SEC.gov ↗ |
| MBX Biosciences, Inc. | 13G amendment | 7.8% | 3,772,885 | Nov 16, 2026 | SEC.gov ↗ |
| Obsidian Therapeutics, Inc. | 13G | 6.6% | 4,101,576 | Oct 5, 2026 | SEC.gov ↗ |
| Spyre Therapeutics, Inc. | 13G | 5.1% | 4,457,450 | Oct 1, 2026 | SEC.gov ↗ |
| Tyra Biosciences, Inc. | 13G | 5.8% | 3,473,453 | Sep 17, 2026 | SEC.gov ↗ |
| Arcellx, Inc. | 13G amendment | 0% | 0 | Aug 14, 2026 | SEC.gov ↗ |
| Assembly Biosciences, Inc. | 13G amendment | 7.8% | 1,553,748 | Aug 14, 2026 | SEC.gov ↗ |
| Edgewise Therapeutics, Inc. | 13G amendment | 9.5% | 10,215,455 | Aug 14, 2026 | SEC.gov ↗ |
| Maze Therapeutics, Inc. | 13G amendment | 0% | 0 | Aug 14, 2026 | SEC.gov ↗ |
| EyePoint, Inc. | 13G amendment | 3.8% | 3,142,437 | May 15, 2026 | SEC.gov ↗ |
| UroGen Pharma Ltd. | 13G amendment | 3.5% | 1,703,949 | May 15, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 24 companies. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (6)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (1)
As reported in the adviser's Form ADV filed Sep 20, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures